Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 106,038

Document Document Title
WO/2015/099167A1
Provided are: a vaccine against IL-17A, said vaccine using a polypeptide as an immunogen, and said polypeptide including the amino acid sequence shown in SEQ ID NO: 1 or including a non-human mammal derived amino acid sequence correspond...  
WO/2015/098591A1
1-(Benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is already known to exhibit an excellent activity/effect as an anti-depression drug, a psychotropic drug, an anti-Parkinson's disease d...  
WO/2015/098991A1
The purpose of the present invention is to provide a novel compound, which strongly inhibits metabotropic glutamate receptor 5 signal transduction. The present invention provides the N-alkylamide derivative represented below or a pharmac...  
WO/2015/096187A1
Disclosed are a stable crystal I-form agomelatine tablet and a preparation method thereof. The preparation method thereof comprises the following steps: adding one or more protective agents into pure water, stirring, heating the mixture ...  
WO/2015/099102A1
The purpose of the present invention is to provide a sleep-improving agent by which a feeling of deep sleep is obtained, a non-REM sleep time-increasing agent, and a sedative. The sleep-improving agent of the present invention contains z...  
WO/2015/097546A1
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R'-R3 are defined as set forth in the specification. The invention is also directed to use of compounds of Formul...  
WO/2015/096186A1
Disclosed are a stable crystal X-form agomelatine tablet and a preparation method thereof. The method comprises the following steps: selecting one or more protective agents, adding the protective agents into pure water, stirring, heating...  
WO/2015/096551A1
An N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, a preparation method and an application. The structure of the compound is represented by formula (I). The compound can generate a rapid and rever...  
WO/2015/099094A1
 It is now understood that, from the preclinical stage of Alzheimer's disease, abnormalities in spine formation and the like occur due to worsening phosphorylation of MARCKS and the like, thereby leading to the onset of the disease in ...  
WO/2015/098857A1
Provided is a hydrated crystal of 4-(((6S,9S)-1-(benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(qu inolone-8-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazi ne-6-yl)methyl)phenyl dihydrogen phosphate, said crystal having a diffraction pea...  
WO/2015/097463A1
The invention relates to pharmaceutically active compounds having improved pharmacokinetic properties and being useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain i...  
WO/2015/095970A1
Covalent conjugates between lipoic acid (LA), or a derivative thereof, and edaravone, or a derivative thereof, are disclosed, including compounds of Formula I: (I) Therapeutic methods using the LA-edaravone conjugates are also described,...  
WO/2015/095918A1
The invention relates to a method of treating or preventing pain, or a condition associated with pain, in a subject in need thereof, comprising applying topically an effective amount of an extract of Zingiber Officinale (ginger), and to ...  
WO/2015/100252A1
Felbamate deuterated at the 2 position, compositions containing the same, and methods of making and using thereof are described herein. Substitution of the hydrogen at the 2 position with deuterium should prevent or reduce formation of t...  
WO/2015/100217A1
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is g...  
WO/2015/099107A1
A compound expressed by formula (I) (in the formula: Z1 is C(R2) or N; Z3 is CH or N; Z2 is C(R3) or N, and when Z2 is N, Z1 is C(R2) and Z3 is CH; A-ring is a substituted or unsubstituted aromatic carbon ring, etc.; R1 is a substituted ...  
WO/2015/095968A1
Described are covalent conjugates between lipoic acid (LA), or a derivative thereof, and resveratrol, or a derivative thereof. As an example, the covalent conjugate may be a compound of the formula: (I). Methods using the LA-resveratrol ...  
WO/2015/097461A1
A compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, Wherein Q, R2, Ar, A and R1 are as defined in claim 1. The claimed compounds are gap junction blockers useful for the treatment or prevention of a range o...  
WO/2015/096771A1
Provided in the present invention are a compound having a structural feature of the general formula I as a novel retinoic acid orphan nuclear receptor γ subtype (RORγ) inhibitor, and the uses of the compound and a pharmaceutically acce...  
WO/2015/098441A1
Provided are a sleeping aid, a non-REM sleep time increasing agent, and a sedative with which a sense of deep sleep can be obtained. The sleeping aid, non-REM sleep time increasing agent, and sedative comprise an alpha-lipoic acid as an ...  
WO/2015/098963A1
Provided is a method for promoting the expression of calreticulin in at least one type of eukaryotic cell. Also provided is a synthetic peptide that can be used in said method. The method provided by the present invention includes prepar...  
WO/2015/097545A1
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, Y, Z, and G are defined as set forth in the specification. The invention is also directed to use of compo...  
WO/2015/097548A1
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R1a, R1b, R1c, X, Y, Z, G, O, W1 and W2 are defined as set forth in the specification. The invention is also ...  
WO/2015/100353A1
Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimers disease. Also described are methods, systems and compositions to distinguish between Alzheimers disease and Park...  
WO/2015/096654A1
The present invention relates to the application of a specific inhibitor for an SHH signaling pathway. Disclosed for the first time are that the SHH signaling pathway and excitability of neural networks have a close relationship and are ...  
WO/2015/097611A1
Disclosed are compositions comprising melatonin and astragaloside IV or astragalus extracts containing it.  
WO/2015/096651A1
Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses t...  
WO/2015/099841A1
In one aspect, the present disclosure provides indazoles of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R3, R4, R5, R6, Z1, Z2, Z3, and G are defined as set forth in the specification. Further, ...  
WO/2015/095963A1
The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize glucocerebrosidases and enhance their enzymatic activity in vivo. Such compounds, prodrugs and compositions thereof are useful in trea...  
WO/2015/099196A1
The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, am...  
WO/2015/090226A1
The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usa...  
WO/2015/095548A1
The subject invention provides methods of treating or delaying disease progression in a subject afflicted with Huntington's disease (HD) comprising administering to the subject 0.5-1.5 mg/day laquinimod. The subject invention also provid...  
WO/2015/091805A1
The present invention provides Quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.  
WO/2015/092804A1
The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to meth...  
WO/2015/092043A1
The present invention relates to the combined use of bezafibrate and of resveratrol or resveratrol derivatives for the treatment of diseases involving a mitochondrial energy dysfunction, and also to a pharmaceutical kit comprising both b...  
WO/2015/091656A1
The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.  
WO/2015/091647A1
A compound of formula (I) or a salt thereof are provided wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions ass...  
WO/2015/093515A1
A medicine comprising a 1-indansulfamide compound such as N-[(1s)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-indene-1-yl]sulfa mide, or N-[(1s)-2,2-difluoro-7-methyl-2,3-dihydro-1H-indene-1-yl]sul famide, or a pharmaceutically acceptable salt th...  
WO/2015/093567A1
The present invention is a pain-related compound, a medicinal composition, and uses thereof. One or multiple embodiments are a compound represented by formula (I), a prodrug thereof, or a pharmaceutically permissible salt thereof.  
WO/2015/095728A1
The present invention provides compounds of formula (I): which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and interm...  
WO/2015/095059A1
The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ASK1), thus are thus useful in treating ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, c...  
WO/2015/090233A1
Provided herein are novel aromatic heterocyclic compounds or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for trea...  
WO/2015/091795A1
The present invention relates to new fused imidazolyl derivatives having a high affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprising them, and to th...  
WO/2015/095387A1
The present disclosure relates to an oral, extended release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogeneously spread throughout a matrix used to deter abuse. The pi...  
WO/2015/093534A1
[Problem] To provide a novel triazinone compound having inhibitory activity on T-type potential-dependent calcium channels, and which is useful for treating pain, chronic kidney disease, and atrial fibrillation in particular. [Solution] ...  
WO/2015/090122A1
The present invention relates to a phenyl benzyl ether derivative and a preparation method and use thereof, and a part of the compound act as an A beta plaque imaging agent after being radioactively nuclide labelled, and the phenyl benzy...  
WO/2015/091988A1
The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to piperidene compounds having this pharmacological activity, to proces...  
WO/2015/090232A1
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also pro...  
WO/2015/091889A1
The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, ...  
WO/2015/091411A1
The present invention provides spiro-oxazolones, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The presen...  

Matches 51 - 100 out of 106,038